Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07210723 · ClinicalTrials.gov registry record · Phase 2
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
A Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy, sponsored by Kardigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 332
- Enrollment target
- 18
- Study locations
NCT07210723 is a Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy that is actively recruiting participants, run by Kardigan. The registered enrollment target is 332 participants. The trial reports 18 study locations across 12 states.
The verdict
NCT07210723, a Phase 2 study of Symptomatic Genetic Dilated Cardiomyopathy, is actively recruiting participants, sponsored by Kardigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 332 participants
- Enrollment target
- 18
- Study locations
Study Summary
The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM. The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood; this can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM). The main goals of the study are: * To assess the effect of danicamtiv on cardiac function using echocardiogram. * To evaluate the impact of danicamtiv on exercise capacity * To evaluate the safety and tolerability of danicamtiv Participants will: * Take danicamtiv or placebo every day for approximately 6 months * Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up
Conditions Studied
Interventions
- DRUG Placebo
- DRUG danicamtiv
Study Locations (18)
Other
- Hospital Universitario de A Coruña - A Coruña
- Hospital Clinico Universitario Virgen de la Arrixaca - Murcia
- Hospital Universitario Virgen del Rocio - Seville
- NHS Greater Glasgow and Clyde - Glasgow
- Royal Brompton Hospital - London
- Hammersmith Hospital, Imperial College of London - London
California
- Cedars Sinai - Los Angeles
- UCSF - San Francisco
Alabama
- University of Alabama Birmingham - Birmingham
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Massachusetts
- Brigham and Women's Hospital - Boston
Michigan
- Henry Ford Health System - Detroit
Minnesota
- Mayo Clinic Rochester - Rochester
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2026-02-13 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07210723
The ClinicalTrials.gov registry entry for NCT07210723 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 332 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kardigan, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Genetic Dilated Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07210723 reports 18 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07210723 about?
NCT07210723 is a clinical study titled "A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy". The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs t...
What is the current status of trial NCT07210723?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 332 participants. The study started on 2026-02-13. Estimated completion is 2028-01.
What conditions does trial NCT07210723 study?
This clinical trial studies the following conditions: Symptomatic Genetic Dilated Cardiomyopathy.
What interventions are being tested in trial NCT07210723?
The interventions under investigation include: Placebo (DRUG), danicamtiv (DRUG).
Who is sponsoring clinical trial NCT07210723?
This trial is sponsored by Kardigan, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07210723 being conducted?
This trial has 18 study locations across Alabama, California, District of Columbia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.